“Biopharmaceuticals Manufacturing Consumables Testing Market Report is set to have rapid growth due to technological advancements and changing or improving regulatory requirements for analysis of raw materials required during biologics manufacturing at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Biopharmaceuticals Manufacturing Consumables Testing Market Forecast 2019-2029: By Service (Compendial Testing, Laboratory Testing), By Raw Material Type (Excipients, API), Regions and segmental Forecasts.
Effective and successful biopharmaceutical production largely depends on the purity and quality of consumables used during production. With increasing problems related to the quality of new therapies such as poor solubility, increased molecular size and poor absorption properties, there is an increase in attention in the exploration of the various attributes of excipients and other raw materials.
The rapid growth of the biopharmaceutical industry has made it necessary to keep pace with the change or improvement of regulatory requirements for the analysis of raw materials required during organic production. Consequently, manufacturers of final products require the support of the supplier qualification program to validate whether the services offered by the supplier are in compliance with the complementary monographs. This led the segment to support the supplier qualification program based on compendial methods. In addition, technological advances in analytical technologies have provided suppliers with improved capabilities to test proteins, raw materials, cell lines and other consumables used during the production of large molecules. Advances in portable Raman spectroscopy methods are one of the significant developments in this market. Agilent Technologies is one of the companies that offers products based on the principle of Raman spectroscopy.
Leading companies featured in the report include Alcami Corporation; Merck KGaA; Eurofins Scientific; Agilent Technologies; Charles River; Catalent, Inc.; Avomeen Analytical Services; BioSpectra; Pace Analytical Services, LLC and Gibraltar Laboratories
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.